Xian-Wu Cheng

Prof. Dr. Xian-Wu Cheng

Cardiology and Hypertension, Yanbian University Hospital, Yanji, Jilin, China
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2012 in Circulation
Verified
Journal Article
Closed access
XCXian-Wu Cheng
Xian-Wu Cheng
GSGuo-Ping Shi
Guo-Ping Shi
MKMasafumi Kuzuya
Masafumi Kuzuya
TSTakeshi Sasaki
Takeshi Sasaki
KOKenji Okumura
Kenji Okumura
TMToyoaki Murohara
Toyoaki Murohara

1 December 2011 in Hypertension
Verified
Journal Article
Closed access
XCXian-Wu Cheng
Xian-Wu Cheng
ZHZhe Huang
Zhe Huang
MKMasafumi Kuzuya
Masafumi Kuzuya
KOKenji Okumura
Kenji Okumura
TMToyoaki Murohara
Toyoaki Murohara
Atherosclerosis-based vascular disease is an inflammatory disease characterized by extensive remodeling of the extracellular matrix architecture of the arterial wall. Although matrix metalloproteinases and serine proteases participate in these pathological events, the discovery of cysteine protease cathepsins, such as cathepsins K, S, L, and B, and cystatin C, and their tissue distribution has suggested that at least some of them participate in cardiovascular disease. Studies on vascular cells have shown that atherosclerosis-associated inflammatory cytokines augment cysteinyl cathepsin expression and activity. Novel insight into cathepsin functions has been made possible by the generation and in-depth analysis of knockout and transgenic mice. These studies have provided direct evidence implicating cathepsins in atherosclerosis-based vascular disease through the activation, liberation, and modification of angiogenic growth factors, cytokines, and proteases associated with lipid metabolism, cell events (migration, invasion, proliferation, and apoptosis), angiogenesis, and matrix protein remodeling. Furthermore, evaluation of the feasibility of cathepsins as a diagnostic tool has revealed that the serum cathepsins S and L and the endogenous inhibitor cystatin C hold promise as biomarkers of coronary artery disease and aneurysm formation. The goal of this review is to summarize the available information regarding the mechanistic contributions of cathepsins in atherosclerosis-based vascular disease.

1 January 2018 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
HWHongxian Wu
Hongxian Wu
QDQiuna Du
Qiuna Du
QDQiuyan Dai
Qiuyan Dai
JGJunbo Ge
Junbo Ge
XCXian-Wu Cheng
Xian-Wu Cheng
Atherosclerotic cardiovascular disease (ASCVD) is an inflammatory disease characterized by extensive arterial wall matrix protein degradation. Cysteine protease cathepsins play a pivotal role in extracellular matrix (ECM) remodeling and have been implicated in the development and progression of atherosclerosis-based cardiovascular diseases. An imbalance in expression between cathepsins (such as cathepsins S, K, L, C) and their inhibitor cystatin C may favor proteolysis of ECM in the pathogenesis of cardiovascular disease such as atherosclerosis, aneurysm formation, restenosis, and neovascularization. New insights into cathepsin functions have been made possible by the generation of knockout mice and by the application of specific inhibitors. Inflammatory cytokines regulate the expression and activities of cathepsins in cultured vascular cells and macrophages. In addition, evaluations of the possibility of cathepsins as a diagnostic tool revealed that the circulating levels of cathepsin S, K, and L, and their endogenous inhibitor cystatin C could be promising biomarkers in the diagnosis of coronary artery disease, aneurysm, adiposity, peripheral arterial disease, and coronary artery calcification. In this review, we summarize the available information regarding the mechanistic contributions of cathepsins to ASCVD.

30 March 2007 in Circulation Research
Verified
Journal Article
Closed access
PDF file
XCXian-Wu Cheng
Xian-Wu Cheng
MKMasafumi Kuzuya
Masafumi Kuzuya
KNKae Nakamura
Kae Nakamura
KMKeiko Maeda
Keiko Maeda
MTMichitaka Tsuzuki
Michitaka Tsuzuki
TMToyoaki Murohara
Toyoaki Murohara
Matrix metalloproteinases (MMPs) have been implicated in the process of neovascularization. However, the exact roles of individual MMPs in vessel formation are poorly understood. To study the putative role of MMP-2 in ischemia-induced neovascularization, a hindlimb ischemia model was applied to MMP-2 +/+ and MMP-2 −/− mice. Serial laser Doppler blood-flow analysis revealed that the recovery of the ischemic/normal blood-flow ratio in MMP-2 −/− young and old mice remained impaired throughout the follow-up period. At day 35, microangiography and anti– l -lectin immunohistochemical staining revealed lesser developed collateral vessels and capillary formation in both old and young MMP-2 −/− mice compared with the age-matched MMP-2 +/+ mice. An aortic-ring culture assay showed a markedly impaired angiogenic response in MMP-2 −/− mice, which was partially recovered by supplementation of the culture medium with recombinant MMP-2. Aorta-derived endothelial cells or bone marrow–derived endothelial progenitor cell (EPC)-like c-Kit + cells from MMP-2 −/− showed marked impairment of invasive or/and proliferative abilities. At day 7, plasma and ischemic tissues of vascular endothelial growth factor protein were reduced in MMP-2 −/− . Flow cytometry showed that the numbers of EPC-like CD31 + c-Kit + cells in peripheral blood markedly decreased in MMP-2–deficient mice. Transplantation of bone marrow–derived mononuclear cells from MMP-2 +/+ mice restored neovascularization in MMP-2 −/− young mice. These data suggest that MMP-2 deficiency impairs ischemia-induced neovascularization through a reduction of endothelial cell and EPC invasive and/or proliferative activities and EPC mobilization.

1 November 2006 in Hypertension
Verified
Journal Article
Closed access
XCXian-Wu Cheng
Xian-Wu Cheng
KOKoji Obata
Koji Obata
MKMasafumi Kuzuya
Masafumi Kuzuya
HIHideo Izawa
Hideo Izawa
KNKae Nakamura
Kae Nakamura
MYMitsuhiro Yokota
Mitsuhiro Yokota
Cathepsins are cysteine proteases that participate in various types of tissue remodeling. However, their expressions during myocardial remodeling have not been examined. In this study, we investigated their expressions in the left ventricular (LV) myocardium of rats and humans with hypertension-induced LV hypertrophy or heart failure (HF). Real-time PCR and immunoblot analysis revealed that the abundance of cathepsin S mRNA or protein in the LV tissues was greater in rats or humans with HF than in those with hypertrophy or in control subjects. Immunostaining showed that cathepsin S was localized predominantly to cardiac myocytes and coronary vascular smooth muscle cells, but also overlapped in part with macrophages. Elastic lamina fragmentations significantly increased in the LV intramyocardial coronary arteries of HF rats. The amount of elastolytic activity in the extract of the LV myocardium was markedly increased for HF rats compared with controls, and this activity was mostly because of cathepsin S. Although the amount of elastin mRNA was increased in the LV myocardium of HF rats, the area of interstitial elastin was not. The expression of interleukin 1β was increased in the LV myocardium of HF rats, and this cytokine was found to increase the expression and activity of cathepsin S in cultured neonatal cardiomyocytes. These results suggest that cathepsin S participates in pathological LV remodeling associated with hypertension-induced HF. This protease is, thus, a potential target for therapeutics aimed at preventing or reversing cardiac remodeling.

29 November 2016 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
AIAiko Inoue
Aiko Inoue
XCXian-Wu Cheng
Xian-Wu Cheng
ZHZhe Huang
Zhe Huang
LHLina Hu
Lina Hu
RKRyosuke Kikuchi
Ryosuke Kikuchi
MKMasafumi Kuzuya
Masafumi Kuzuya
Background: Exercise train (ET) stimulates muscle response in pathological conditions, including aging. The molecular mechanisms by which exercise improves impaired adiponectin/adiponectin receptor 1 (AdipoR1)‐related muscle actions associated with aging are poorly understood. Here we observed that in a senescence‐accelerated mouse prone 10 (SAMP10) model, long‐term ET modulated muscle‐regenerative actions.Methods: 25‐week‐old male SAMP10 mice were randomly assigned to the control and the ET (45 min/time, 3/week) groups for 4 months. Mice that were maintained in a sedentary condition served controls.Results: ET ameliorated aging‐related muscle changes in microstructure, mitochondria, and performance. The amounts of proteins or mRNAs for p‐AMPKα, p‐Akt, p‐ERK1/2, p‐mTOR, Bcl‐XL, p‐FoxO3, peroxisome proliferators‐activated receptor‐γ coactivator, adiponectin receptor1 (adpoR1), and cytochrome c oxidase‐IV, and the numbers of CD34+/integrin‐α7+ muscle stem cells (MuSCs) and proliferating cells in the muscles and bone‐marrow were enhanced by ET, whereas the levels of p‐GSK‐3α and gp91phox proteins and apoptotic cells were reduced by ET. The ET also resulted in increased levels of plasma adiponectin and the numbers of bone‐marrow (BM)‐derived circulating CD34+/integrin‐α7+ MuSCs and their functions. Integrin‐α7+ MuSCs of exercised mice had improved changes of those beneficial molecules. These ET‐mediated aged muscle benefits were diminished by adiponectin and AdipoR1 blocking as well as AMPK inhibition. Finally, recombinant mouse adiponectin enhanced AMPK and mTOR phosphorylations in BM‐derived integrin‐α7+ cells.Conclusions: These findings suggest that ET can improve aging‐related impairments of BM‐derived MuSC regenerative capacity and muscle metabolic alterations via an AMPK‐dependent mechanism that is mediated by an adiponectin/AdipoR1 axis in SAMP10 mice.